Catherine S. Grasso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Catherine S. Grasso has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Arul M. Chinnaiyan
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
18 shared publications - Chandan Kumar-Sinha
University of Michigan 7 Michigan Center for Translational Pathology Ann Arbor, Michigan
18 shared publications - Dan R. Robinson
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI
18 shared publications - Diane M. Simeone
Moores Cancer Center, UC San Diego Health, San Diego, USA
18 shared publications - Iris Wei
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
18 shared publications Linda W. Ma
18 shared publications
Latest Publications
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 1. A general workflow and method of NanoVelcro CTC Enumeration Assay.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 1. A general workflow and method of NanoVelcro CTC Enumeration Assay.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 5. Western-blot of EMD in 22Rv1 and C4-2B EMD-knockdown cells by shRNA.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 5. Western-blot of EMD in 22Rv1 and C4-2B EMD-knockdown cells by shRNA.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 1. Real-time PCR Oligonucleotide Sequence.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 1. Real-time PCR Oligonucleotide Sequence.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 4. Western-blot of EMD in 22Rv1 EMD-knockdown cells by siRNA.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 4. Western-blot of EMD in 22Rv1 EMD-knockdown cells by siRNA.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 2. vsnCTCs are associated with poorer clinical outcomes in advanced prostate cancer.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 2. vsnCTCs are associated with poorer clinical outcomes in advanced prostate cancer.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 2. Univariate and multivariable Cox regression analyses.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 2. Univariate and multivariable Cox regression analyses.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 6. Cell Viability of 22Rv1 EMD knockdown cells by shRNA after 5 days treatment of 10 µM abiraterone acetate A), and 5 µM enzalutamide (ENZA) B).
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 6. Cell Viability of 22Rv1 EMD knockdown cells by shRNA after 5 days treatment of 10 µM abiraterone acetate A), and 5 µM enzalutamide (ENZA) B).
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 3. P-spline curve comparing CTC number and hazard ratio for overall survival.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Figure 3. P-spline curve comparing CTC number and hazard ratio for overall survival.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 4. Univariate and multivariable Cox regression analyses for patients with detectable CTCs adjusted for minimum nuclear size.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 4. Univariate and multivariable Cox regression analyses for patients with detectable CTCs adjusted for minimum nuclear size.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 3. All subsequent treatments after vsnCTC assessment.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer
Supplemental Table 3. All subsequent treatments after vsnCTC assessment.